RA Capital and RTW Investments led a $125m Series B round in GH Research, a privately-held clinical-stage biopharmaceutical company, with participation from BVF Partners, Acuta Capital Partners, Boxer Capital, Cormorant Asset Management, Deerfield Management Company, Logos Capital, Surveyor Capital, Venrock Healthcare Capital Partners and Verition Fund Management. GH Research plans to advance GH001 into clinical development in additional psychiatric and neurological disorders beyond Treatment-Resistant Depression. The company also plans to advance GH002, its injectable 5-MeO-DMT product candidate, into clinical development, as well as explore additional drug delivery approaches.